Vaccine-breakthrough infection by the SARS-CoV-2 omicron variant elicits broadly cross-reactive immune responses

Clin Transl Med. 2022 Jan;12(1):e720. doi: 10.1002/ctm2.720.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • COVID-19 / immunology*
  • COVID-19 / prevention & control
  • COVID-19 Vaccines / administration & dosage
  • COVID-19 Vaccines / immunology*
  • Cross Reactions
  • Female
  • Humans
  • Male
  • SARS-CoV-2 / immunology*

Substances

  • COVID-19 Vaccines

Supplementary concepts

  • SARS-CoV-2 variants